Evidence map›Paper›PMID 34149296›Full record

ReviewCurrent opinion in colloid & interface science2021

Surfactants - Compounds for inactivation of SARS-CoV-2 and other enveloped viruses.

Miriam Simon, Michael Veit, Klaus Osterrieder, Michael Gradzielski

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in colloid & interface science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Membrane-Targeting Antivirals.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. SARS-CoV-2 FP1 Destabilizes Lipid Membranes and Facilitates Pore Formation.International journal of molecular sciences · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Effectiveness of TRIzol in Inactivating Animal Pathogens.Applied biosafety : journal of the American Biological Safety Association · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Miriam SimonDept. of Chemical Engineering and the Russell Berrie Nanotechnolgy Inst. (RBNI), Technion-Israel Institute of Technology, Haifa, IL 3200003, Israel.
Michael VeitInstitut für Virologie, Fachbereich Veterinärmedizin, Freie Universität Berlin, Robert von Ostertag-Straße 7-13, 14163 Berlin, Germany.
Klaus OsterriederInstitut für Virologie, Fachbereich Veterinärmedizin, Freie Universität Berlin, Robert von Ostertag-Straße 7-13, 14163 Berlin, Germany.
Michael GradzielskiStranski-Laboratorium für Physikalische und Theoretische Chemie, Institut für Chemie, Straße des 17. Juni 124, Sekr. TC7, Technische Universität Berlin, D-10623 Berlin, Germany.
City University of Hong Kong · HKFreie Universität Berlin · DETechnion – Israel Institute of Technology · ILTechnische Universität Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We provide here a general view on the interactions of surfactants with viruses, with a particular emphasis on how such interactions can be controlled and employed for inhibiting the infectivity of enveloped viruses, including coronaviruses. The aim is to provide to interested scientists from different fields, including chemistry, physics, biochemistry, and medicine, an overview of the basic properties of surfactants and (corona)viruses, which are relevant to understanding the interactions between the two. Various types of interactions between surfactant and virus are important, and they act on different components of a virus such as the lipid envelope, membrane (envelope) proteins and nucleocapsid proteins. Accordingly, this cannot be a detailed account of all relevant aspects but instead a summary that bridges between the different disciplines. We describe concepts and cover a selection of the relevant literature as an incentive for diving deeper into the relevant material. Our focus is on more recent developments around the COVID-19 pandemic caused by SARS-CoV-2, applications of surfactants against the virus, and on the potential future use of surfactants for pandemic relief. We also cover the most important aspects of the historical development of using surfactants in combatting virus infections. We conclude that surfactants are already playing very important roles in various directions of defence against viruses, either directly, as in disinfection, or as carrier components of drug delivery systems for prophylaxis or treatment. By designing tailor-made surfactants, and consequently, advanced formulations, one can expect more and more effective use of surfactants, either directly as antiviral compounds or as part of more complex formulations.

Indexed as

AFM, atomic force microscopyBVDV, Bovine Viral Diarrhea VirusC12E8, dodecyloctaglycolcac, critical aggregate concentrationcmc, critical micelle concentrationCPyC, cetylpyridinium chlorideDisinfectionDSPC, 1,2-distearoyl-sn-glycero-3-phosphocholineEnveloped virusesFlu, influenza virusHIV, human immunodeficiency virusHSV, herpes simplex virusITC, isothermal titration calorimetryLd, liquid-disorderedLipid bilayersLo, liquid-orderedPA, phosphatidic acid (anionic)PC, phosphatidylcholine (zwitterionic)PE, phosphatidylethanolamine (zwitterionic)PI, phosphatidylinositol (anionic)POPC, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholinep, packing parameterPS, phosphatidylserine (anionic)QUAT, quaternary alkyl ammoniumRNP, ribonucleoprotein particleSAXS, small-angle X-ray scatteringSDS, sodium dodecyl sulphateSurfactantTBP, tri-n-butyl phosphateTEM, transmission electron microscopyVirus inactivation

Identifiers

PMID34149296
PMCPMC8196227
OpenAlexW3172434593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.